Skip to main content
Trillium
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • CD47
  • Pipeline
    • Overview
    • TTI-621
    • TTI-622
  • For Patients
    • Overview
    • TTI-621-01
    • TTI-622-01
  • Investors
  • Contact
    • Contact Information
    • Careers
  • Menu
  • Investors
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
  • Corporate Governance
    • Management Team
    • Board of Directors
    • Governance Documents
    • 2020 Annual Meeting
  • Press Releases
  • Events & Presentations
  • Investor Resources
    • Contact Investor Relations
    • FAQs
    • Email Alerts
    • RSS

SEC Filing Details

Form 4

January 11, 2021
Statement of Changes in Beneficial Ownership
  • PDF Format Download (opens in new window)
  • Word Format Download (opens in new window)
  • Excel Format Download (opens in new window)

Cambridge Office

100 Cambridgepark Drive, Suite 510
Cambridge, MA 02140
USA
Tel: +1 857.412.7029

Mississauga Office

2488 Dunwin Drive
Mississauga, ON L5L 1J9
Canada
Tel: +1 416.595.0627

INVESTOR RELATIONS

James Parsons
Chief Financial Officer
Tel: +1 416.595.0627 x232
james@trilliumtherapeutics.com

GENERAL

info@trilliumtherapeutics.com




© Copyright - Trillium Therapeutics Inc. | Graphics © Audra Geras | Terms of Use
  • About
  • Science
  • Pipeline
  • For Patients
  • Investors
  • Contact
Powered By Q4 Inc. 5.52.0.6 (opens in new window)